An overview on antiepileptic drugs

Drug Discoveries & Therapeutics

Volumn 6, Issue 4, 2011, Pages 178-193

  Das, Nirupam ^a   Dhanawat, Meenakshi ^a   Shrivastava, Sushant ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

anticonvulsants; combination therapy; Epilepsy; resistance

Indexed keywords

EID: 85008731687     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2012.v6.4.178     Document Type: Article

References (143)

1. Riviello JJ. Classification of seizures and epilepsy. Curr Neurol Neurosci Rep. 2003; 3:325-331.
2. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet. 2001; 357:216-222.
3. Eriksson KJ, Koivikko MJ. Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. Epilepsia. 1997; 38:1275-1282.
4. Robinson S. Systemic prenatal insults disrupt telencephalon development: Implications for potential interventions. Epilepsy Behav. 2005; 7:345-363.
5. Engelborghs S, D'Hooge R, De Deyn PP. Pathophysiology of epilepsy. Acta Neurol Belg. 2000; 100:201-213.
6. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006; 367:1087-1100.
7. Granata T, Cross H, Theodore W, Avanzini G. Immune-mediated epilepsies. Epilepsia. 2011; 52:5-11.
8. Berg AT, Scheffer IE. New concepts in classification of the epilepsies: entering the 21st century. Epilepsia. 2011; 52:1058-1062.
9. World Health Organization. Epilepsy. http://www.who.int/ mediacentre/factsheets/fs999/en/ (accessed July 29, 2012).
10. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008; 12:540-546.
11. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011; 10:446-456.
12. Pearce JMS. Bromide. The first effective antiepileptic agent. J Neurol Neurosurg Psychiatry. 2002; 72:412.
13. Cereghino JJ. The major advances in epilepsy in the 20th century and what we can expect (hope for) in the future. Epilepsia. 2009; 50:351-357.
14. Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, Abrahamsen B, Mattsson JP, Lehmann A, Bettler B, Bräuner-Osborne H. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol. 2002; 61:1377-1384.
15. Parker DA, Ong J, Marino V, Kerr DI. Gabapentin activates presynaptic GABA B heteroreceptors in rat cortical slices. Eur J Pharmacol. 2004; 495:137-143.
16. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006; 6:108-113.
17. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics. Acta Neurol Scand. 2008; 118:69-86.
18. Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia. 1997; 38:S45-S51.
19. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia. 2009; 50:163-173.
20. Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsy. Brain Dev. 2008; 30:549-555.
21. McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology. 2003; 61:1690-1694.
22. Parisi P, Bombardieri R, Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol. 2007; 11:331-336.
23. Landmark CJ. Targets for antiepileptic drugs in the synapse. Med Sci Monit. 2007; 13:RA1-RA7.
24. Borowicz KK, Zadrozniak M, Luszczki JJ, Czuczwar SJ. Interactions between tiagabine and conventional antiepileptic drugs in the rat model of complex partial seizures. J Neural Transm. 2008; 115:661-667.
25. Bauer J, Cooper-Mahkorn D. Tiagabine: Efficacy and safety in partial seizures-current status. Neuropsychiatr Dis Treat. 2008; 4:731-736.
26. Messenheimer JA. Lamotrigine. Epilepsia. 1995; 36: S87-S95.
27. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Valles AS, Lukas RJ, Barrantes FJ, Wu J. The anticonvulsive drug lamotrigine blocks neuronal a4p2 nicotinic acetylcholine receptors. Pharmacol Exp Ther. 2010; 335:401-408.
28. Mackay FJ, Wilton LV, Peace GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997; 38:881-886.
29. Pugazhendhy S, Shrivastava PK, Sinha SK, Shrivastava SK. Lamotrigine-dextran conjugates-synthesis, characterization, and biological evaluation. Med Chem Res. 2001; 20:595-600.
30. Blaszczyk B, Czuczwar SJ. Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients. Neuropsychiatr Dis Treat. 2010; 6:145-150.
31. Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, Saiers J, Adams B, Hammer A, Vuong A, Messenheimer J. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav. 2010; 19:352-358.
32. Knoester PD, Keyser A, Renier WO, Egberts ACG, Hekster YA, Deckers CLP. Effectiveness of lamotrigine in clinical practice: Results of a retrospective population-based study. Epilepsy Res. 2005; 65:93-100.
33. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet. 2007; 369:1000-1015.
34. Shorvon S. Oxcarbazepine: A review. Seizure. 2000; 9:75-79.
35. Schmidt D. Felbamate: Successful development of a new compound for the treatment of epilepsy. Epilepsia. 1993; 34:S30-S33.
36. Mazarati AM, Sofia RD, Wasterlain CG. Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus. Seizure. 2002; 11:423-430.
37. Roecklein BA, Sacks HJ, Mortko H, Stables J. Fluorofelbamate. Neurotherapeutics. 2007; 4:97-101.
38. Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem. 2008; 2:21-39.
39. Novak GP, Kelley M, Zannikos P, Klein B. Carisbamate (RWJ-333369). Neurotherapeutics. 2007; 4:106-109.
40. Deshpande LS, Nagarkatti N, Sombati S, DeLorenzo RJ. The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons. Epilepsy Res. 2008; 79:158-165.
41. Nehlig A, Rigoulot MA, Boehrer A. A new drug, RWJ-333369, displays potent antiepileptic properties in genetic models of absence and audiogenic epilepsy. Epilepsia. 2005; 46:215.
42. Grabenstatter HL, Dudek FE. The use of chronic models in antiepileptic drug discovery: The effect of RWJ-333369 on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia. 2004; 45:197.
43. Francois J, Ferrandon A, Koning E, Nehlig A. A new drug RWJ 333369 protects limbic areas in the lithium-pilocarpine model (lipilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures (abstract). Epilepsia. 2005; 46:269.
44. Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia. 2006; 47:1822-1829.
45. Walker MC, Sander JW. Topiramate: A new antiepileptic drug for refractory epilepsy. Seizure. 1996; 5:199-203.
46. Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci. 2003; 23:7069-7074.
47. Rosenfeld WE. Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997; 19:1294-1308.
48. Luna-Tortos C, Rambeck B, Jurgens UH, Loscher W. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009; 26:2464-2470.
49. Ohman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res. 2009; 87:124-129.
50. Grosso S, Galimberti D, Farnetani MA, Cioni M, Mostardini R, Vivarelli R, Di Bartolo RM, Bernardoni E, Berardi R, Morgese G, Balestri P. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure. 2005; 14:183-189.
51. Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, Mao L, Wiegand F, Hulihan J. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: A randomized double-blind clinical trial. Epilepsia. 2010; 51:1970-1977.
52. Hamann M, Sander SE, Richter A. Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. Eur J Pharmacol. 2008; 601:99-102.
53. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995; 286:137-146.
54. Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat. 2009 5:467-476.
55. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004; 101:9861-9866.
56. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Nat Acad Sci U S A. 1999; 96:15268-15273.
57. Zona C, Niespodziany I, Pieri M, Klitgaard H, Margineanu DG. Seletracetam (ucb 44212), a new pyrrolidone derivative, lacks effect on Na+ currents in rat brain neurons in vitro. Epilepsia. 2005; 46:116.
58. Rigo JM, Nguyen L, Hans G, Belachew S, Moonen G, Matagne A, Klitgaard H. Seletracetam (ucb 44212): Effect on inhibitory and excitatory neurotransmission. Epilepsia. 2005; 46:110-111.
59. Matagne A, Margineanu DG, Potschka H, Loscher W, Michel P, Kenda B, Klitgaard H. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Eur J Pharmacol. 2009; 614:30-37.
60. Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N. Seletracetam (UCB 44212). Neurotherapeutics. 2007; 4:117-122.
61. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem. 2004; 47:530-549.
62. Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm. 2007; 114:1547-1551.
63. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and antiepileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008; 154:1662-1671.
64. Rogawski M. Brivaracetam: A rational drug discovery success story. Br J Pharmacol. 2008; 154:1555-1557.
65. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther. 2007; 113:165-183.
66. Baulac M. Introduction to zonisamide. Epilepsy Res. 2006; 68:S3-S9.
67. Leppik IE. Zonisamide: Chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004; 13:S5-S9.
68. Ohtahara S. Zonisamide in the management of epilepsy-Japanese experience. Epilepsy Res. 2006; 68:S25-S33.
69. Zaccara G, Tramacere L, Cincotta M. Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf. 2011; 10:623-631.
70. Kelemen A, Rasonyl G, Neuwirth M, Barcs G, Szucs A, Jakus R, Fabo D, Juhos V, Palfy B, Halasz P. Our clinical experience with zonisamide in resistant generalized epilepsy syndromes. Ideggyogy Sz. 2011; 64:187-192.
71. Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Lacosamide. Nat Rev Drug Discov. 2008; 7:973-974.
72. Luszczki JJ. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009; 61:197-216.
73. Saussele T. Lacosamide. A new antiepileptic drug as adjunctive therapy in patients with partial-onset seizures. Med Monatsschr Pharm. 2008; 31:374-377.
74. Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009; 23:555-568.
75. Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics. 2007; 4:145-148.
76. White HS, Franklin MR, Kupferberg HJ, Schmutz M, Stables JP, Wolf HH. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008; 49:1213-1220.
77. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008; 49:1123-1141.
78. Herman ST. Adopting an Orphan Drug: Rufinamide for Lennox-Gastaut Syndrome. Epilepsy Curr. 2009; 9:72-74.
79. Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, Spalice A, Habetswallner F, Fels A, Verrotti A, D'Aniello A, Mangano S, Balestri A, Curatolo P, Pascotto A. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011; 18:246-251.
80. Vendrame M, Loddenkemper T, Gooty VD, Takeoka M, Rotenberg A, Bergin AM, Eksioglu YZ, Poduri A, Duffy FH, Libenson M, Bourgeois BF, Kothare SV Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neuro. 2010; 43:155-158.
81. Wisniewski CS. Rufinamide: A new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. Ann Pharmacother. 2010; 44:658-667.
82. Labiner DM. DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002; 3:921-923.
83. Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, Jargiello M, Czuczwar SJ. New generation of valproic acid. Pol J Pharmacol. 2004; 56:283-288.
84. Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release. 2008; 126:1-9.
85. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009; 83:1-43.
86. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002; 27:121-130.
87. Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009; 50:454-463.
88. Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology. 2000; 148:336-343.
89. Monaghan EP, McAculey JW, Data JL. Ganaxolone: A novel positive allosteric modulator of the GABAA receptor complex for the treatment of epilepsy. Exp Opin Invest Drugs. 1999; 8:1663-1671.
90. Malphrus AD, Wilfong AA. Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol. 2007; 9:256-267.
91. Pieribone VA, Tsai J, Soufflet C, Rey E, Shaw K, Giller E, Dulac O. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007; 48:1870-1874.
92. Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics. 2009; 6:392-401.
93. Chatterjee SS, Noldner M. Losigamone: From plant extract to antiepileptic drug. CNS Drug Rev. 1997; 3:225-244.
94. Dimpfel W, Chatterjee SS, Noldner M, Ticku MK. Effects of the anticonvulsant losigamone and its isomers on the GABAa receptor system. Epilepsia. 1995; 36:983-989.
95. Srinivasan J, Richens A, Davies JA. The effect of losigamone (AO-33) on electrical activity and excitatory amino acid release in mouse cortical slices. Br J Pharmacol. 1997; 122:1490-1494.
96. Jones FA, Davies JA. The anticonvulsant effects of the enantiomers of losigamone. Br J Pharmacol. 1999; 128:1223-1228.
97. Gebhardt C, Breustedt JM, Noldner M, Chatterjee SS, Heinemann U. The antiepileptic drug losigamone decreases the persistent Na+ current in rat hippocampal neurons. Brain Res. 2001; 920:27-31.
98. Baulac M, Klement S. Efficacy and safety of losigamone in partial seizures: A randomized double-blind study. Epilepsy Res. 2003; 55:177-189.
99. Santangeli S, Sills GJ, Stone TW, Brodie MJ. Differential effects of remacemide and desglycinyl-remacemide on epileptiform burst firing in the rat hippocampal slice. Neurosci Lett. 2002; 321:33-36.
100. Malek R, Borowicz KK, Kimber-Trojnar Z, Sobieszek G, Piskorska B, Czuczwar SJ. Remacemide-a novel potential antiepileptic drug. Pol J Pharmacol. 2003; 55:691-698.
101. Sills GJ, Santangeli S, Forrest G, Brodie MJ. Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res. 2002; 49:247-254.
102. Wesnes KA, Edgar C, Dean AD, Wroe SJ. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav. 2009; 14:522-528.
103. Borowicz KK, Malek R, Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock. Epilepsy Behav. 2007; 11:6-12.
104. Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics. 2007; 4:149-154.
105. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol. 1997; 336:243-249.
106. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005; 67:1009-1017.
107. Roza C, Lopez-Garcia JA. Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres. Pain. 2008; 138:537-545.
108. Czuczwar P, Wojtak A, Cioczek-Czuczwar A, Parada-Turska J, Maciejewski R, Czuczwar SJ, Retigabine: The newer potential antiepileptic drug. Pharmacol Rep. 2010; 62:211-219.
109. Pevarello P, Bonsignori A, Dostert P, Heidempergher F, Pinciroli V, Colombo M, McArthur RA, Salvati P, Post C, Fariello RG, Varasi M. Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanamide derivatives. J Med Chem. 1998; 41:579-590.
110. Fariello RG. Safinamide. Neurotherapeutics. 2007; 4:110-116.
111. Maurizis JC, Madelmont JC, Rapp M, Marijnen C, Cerf MC, Gillardin JM, Lepage F, Veyre A. Disposition and metabolism of 2,6-dimethylbenzamide jV-(5-methyl-3-isoxazolyl) (D2916) in male and female rats. Drug Metab Dispos. 1997; 25:33-39.
112. Perucca E, Kupferberg HJ. Drugs in early clinical development. In: Antiepileptic drugs (Levy RH, Mattson RH, Meldrum BS, Perucca E, eds.). Lippincott Williams & Wilkins, Philadelphia, USA, 2002; pp. 913-992.
113. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000; 356:1638-1642.
114. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006; 34:608-611.
115. Fisher JL. The anticonvulsant stiripentol acts directly on the GABA (A) receptor as a positive allosteric modulator. Neuropharmacology. 2009; 56:190-197.
116. Lees GJ. Pharmacology of AMPA/Kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs. 2000; 59:33-78.
117. De Sarro G, Gitto R, Russo E, Ibbadu GF, Barreca ML, De Luca L, Chimirri A. AMPA receptor antagonists as potential anticonvulsant drugs. Curr Top Med Chem. 2005; 5:31-42.
118. Chimirri A, Gitto R, Zappala M. AMPA receptor antagonists. Exp Opin Ther Patents. 1999; 9:557-570.
119. Donevan SD, Rogawski MA. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993; 10:51-59.
120. Gitto R, Barreca ML, De Luca L, De Sarro G, Ferreri G, Quartarone S, Russo E, Constanti A, Chimirri A. Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist. J Med Chem. 2003; 46:197-200.
121. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: Challenges, incentives, and recent advances. Lancet Neurol. 2007; 6:793-804.
122. Howes JF, Bell C. Talampanel. Neurotherapeutics. 2007; 4:126-129.
123. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011; 11:56-63.
124. Valrocemide licensed for worldwide development, production and marketing. http://www.epilepsy.org.uk/ node/1133 (accessed July 29, 2012).
125. Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): A new antiepileptic drug. Epilepsia. 2001; 42:831-836.
126. Hovinga CA. Valrocemide (Teva/Acorda). Curr Opin Investig Drugs. 2004; 5:101-106.
127. Hamandi K, Sander JW. Pregabalin: A new antiepileptic drug for refractory epilepsy. Seizure. 2006; 15:73-78.
128. Kavoussi R. Pregabalin: From molecule to medicine. Eur Neuropsychopharmacol. 2006; 2:S128-S133.
129. Dworkin RH, Kirkpatrick P. Fresh from the pipeline: Pregabalin. Nat Rev Drug Discov. 2005; 4:455-456.
130. Briggs DE, Lee CM, Spiegel K, French JA. Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. Epilepsy Res. 2008; 82:86-92.
131. Sisodiya SM. Genetics of drug resistance in epilepsy. Curr Neurol Neurosci Rep. 2005; 5:307-311.
132. Pati S, Alexopoulos AV Pharmacoresistant epilepsy: From pathogenesis to current and emerging therapies. Cleve Clin J Med. 2010; 77:457-467.
133. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999; 34:109-122.
134. Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, Heinemann U, Beck H. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol. 2003; 53:469-479.
135. Volk HA, Loscher W. Multidrug resistance in epilepsy: Rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain. 2005; 128:1358-1368.
136. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003; 348:1442-1448.
137. Sanchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Armijo JA, Genetic factors associated with drug-resistance of epilepsy: Relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010; 19:93-101.
138. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group. Cancer. 2006; 106:830-838.
139. Peltola J, Peltola M, Raitanen J, Keranen T, Kharazmi E, Auvinen A. Seizure-freedom with combination therapy in localization-related epilepsy. Seizure. 2008; 17:276-280.
140. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002; 43:365-385.
141. French JA, Faught E. Rational polytherapy. Epilepsia. 2009; 50:63-68.
142. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: Expert opinion. Epilep Behav. 2005; 7: S1-S64.
143. Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam. Epilepsia. 2009; 50:387-397.